Germin8 Ventures Names Dr. Ashlie L. Burkart as Chief Scientific Officer February 4, 2021 CHICAGO – Feb. 3, 2021 – Germin8 Ventures, a purpose-driven venture capital firm backing the founders of technology companies transforming the food system as a means of solving global challenges, today announced the appointment of physician-scientist Dr. Ashlie L Burkart, MD as Chief Scientific Officer. Drawing upon her deep pathology and research background, Dr. Burkart will play a key role in extending Germin8’s scientific capabilities and actively supporting Germin8 portfolio companies. As a double-boarded anatomic and clinical pathologist with expertise in gastrointestinal/liver pathology, Dr. Burkart is uniquely skilled at diagnosing and investigating the nature of gastrointestinal diseases, as well as the laboratory application of biologic, chemical and physical sciences. Since this skill set could be used towards health and nutrition, microbiome, agro-ecology, and climate alike, Dr. Burkart joins Germin8 effectively as a medical-ecologist bringing intellectual horsepower to shepherd a new standard of care for people and the planet, enabled by our food.